Tumor volume and CP score were top predictors of OS, along with liver gross tumor volume, functional liver volume V20, and prior liver-directed therapy.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Adam Wereszczynski was gobsmacked when tests revealed he had liver disease -he now wants to warn others about the dangers of ...

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and aging are locked in a vicious circle: ...

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and aging are locked in a vicious circle: ...

Blocking a key metabolic enzyme helps B cells fight liver tumors, revealing a new immunotherapy pathway for fatty liver–driven cancer in mice.

New FDA approvals in July include therapies for NSCLC, relapsed multiple myeloma, liver cancer, and B-cell malignancies.

Researchers tested more than 65,000 patients with more than 30 solid tumor types and found the rate of HER2 positivity was about 3%.

The FDA has granted Priority Review to durvalumab for the treatment of resectable, early-stage and locally advanced (Stage II-IVA) gastric and gastroesophageal junction cancers.